Green Ribbon Unveils 'Green Scout' RWD Clinical Analysis Platform

GreenRibbon Officially Launches 'GreenScout', an Innovative Clinical Trial Analysis Platform Healthcare fintech company GreenRibbon has officially launched 'GreenScout,' a real-data-based clinical trial analysis platform, declaring a move towards greater efficiency in the new drug development process. This platform was developed to fundamentally address issues commonly encountered by bio-ventures and pharmaceutical companies in the early stages of clinical trials, such as patient number estimation errors or increased costs and research halts due to inappropriate hospital selection. GreenScout leverages vast real medical data, encompassing over 2.7 million individuals and 900 million records, as its core asset. It is characterized by providing specific and realistic data that goes beyond the limitations of statistical estimation, such as patient distribution, diagnosis frequency, treatment patterns, and visit cycles, through in-depth analysis of domestic insurance claim medical records. Key features include precisely extracting real patient populations based on disease, age, and gender using data from 340 medical institutions nationwide, and automatically recommending optimal clinical trial sites. Additionally, AI-based pre-screening helps effectively identify the appropriate patient scale for a protocol, as well as regions and hospitals where recruitment is easy. GreenRibbon laid the foundation for GreenScout by reconstructing the vast data accumulated through its insurance and medical data platform, 'LifeCatch,' into a powerful Real-World Data (RWD) infrastructure usable by pharmaceutical companies and Contract Research Organizations (CROs). Kim Gyu-ri, CEO of GreenRibbon, stated her ambition: "By leveraging Korea's excellent medical infrastructure and data, we aim to maximize the efficiency of clinical trials and significantly reduce uncertainties in the new drug development process." GreenScout is expected to lead the era of data-driven drug development, opening new horizons for the pharmaceutical and bio-industries.